Active, not recruitingNCT05736523
Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)
Studying Neuroendocrine neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Utah
- Principal Investigator
- John Hyngstrom, MDHuntsman Cancer Institute/ University of Utah
- Enrollment
- 28 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2025
Study locations (2)
- Intermountain Medical Center, Murray, Utah, United States
- Huntsman Cancer Institute, Salt Lake City, Utah, United States
Collaborators
Intermountain Medical Center · Natera, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05736523 on ClinicalTrials.govOther trials for Neuroendocrine neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06406465A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and ToxicityNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06202066Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine CarcinomasRoswell Park Cancer Institute
- RECRUITINGPHASE1NCT07224425A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it HelpsBoehringer Ingelheim
- RECRUITINGPHASE2NCT07449754Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant MelanomaHanmi Pharmaceutical Company Limited
- RECRUITINGPHASE2NCT07336147Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical CarcinomaChang Gung Memorial Hospital
- RECRUITINGPHASE1NCT07086105A Study to Evaluate Adze1.C in Participants With Metastatic MelanomaAdze Biotechnology Australia Pty Ltd
- RECRUITINGPHASE2NCT07357623Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine TumorsShanghai Chest Hospital
- RECRUITINGPHASE2NCT07215182[68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in CancerBarbara Malene Fischer